069IC - Evidence-Based Update on Prostate Cancer Detection and Management

Sunday, April 30, 2023

4:00 PM – 6:00 PM CST

Location: S103C

Instructional Course Director(s)

GA

Gerald Andriole, Jr., MD

Johns Hopkins University

Instructional Course Faculty(s)

Anthony D'Amico

Brigham and Women's Hospital
AS

A. Oliver Sartor, MD

Tulane Medical School
CS

Cary Siegel, MD

Professor of Radiology
Mallinckrodt Institute of Radiology
Adam Kibel, MD

Elliott Carr Cutler Professor of Surgery, Chief of Urology
Brigham Health, Harvard University

Course Description: This course will provide a practical update on each of the following areas of prostate cancer: screening and early detection, new biomarkers, new imaging and biopsy techniques, and new agents to manage advanced/metastatic prostate cancer.

Learning Objectives:

Utilize PSA and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.
Classify the principles of “risk-adapted” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores and specific genetic mutations (e.g., BRCA1/2).
Explain the roles of MRI, microultrasound, positron emission tomography PET imaging and novel approaches to improve prostate biopsy.
Explain the emerging role of positron emission tomography imaging in men with prostate cancer, especially those with biochemical recurrence, and the rationale for metastasis-directed therapy in these men.
Describe how to treat men with locally advanced prostate cancer with multimodal approaches.
Describe how to choose and sequence hormonal, chemotherapeutic, immunological, systemic radioligand treatments and/or targeted medications (e.g., PARP inhibitors) in men with metastatic and castrate-resistant prostate cancer.